Audenz (influenza A (H5N1) monovalent vaccine adjuvanted) / CSL Behring - LARVOL DELTA

Influenza-Associated Antibiotic Prescribing and the Potential Impact of More Effective Vaccines on Antimicrobial Stewardship (IDWeek 2026) - No abstract available

Infectious Disease • Influenza

Meta-analysis of Relative Vaccine Effectiveness of Adjuvanted (aTIV/aQIV) vs High-dose Influenza Vaccines (HD-TIV/HD-QIV) for Prevention of Influenza (IDWeek 2026) - No abstract available

Retrospective data • Infectious Disease • Influenza

Clinical and Economic Effects of Expanded Pediatric Influenza Immunization Using Cell‑Based Vaccines in the United States (IDWeek 2026) - No abstract available

Clinical • Infectious Disease • Influenza

Influenza-Associated Antibiotic Prescribing and the Potential Impact of More Effective Vaccines on Antimicrobial Stewardship (IDWeek 2026) - No abstract available

Infectious Disease • Influenza

Heterologous prime-boost vaccination against H5 avian influenza: Safety and immunogenicity of a MF59-adjuvanted, cell-culture derived H5N6 vaccine. (PubMed, Hum Vaccin Immunother) - "This phase 2 extension study evaluated immunogenicity and safety of MF59-adjuvanted, cell culture-derived H5N6 vaccine (aH5N6c) in adults primed with MF59-adjuvanted, cell culture-derived H5N1 vaccine (aH5N1c) and in unprimed adults...Solicited adverse events were mild or moderate, comparable between groups, and consistent with other MF59-adjuvanted pandemic vaccines; no vaccine-related serious adverse events occurred. Heterologous H5N6 booster vaccination in H5N1-primed adults elicited strong cross-reactive immunity against the priming strain, demonstrating long-lasting immune memory for at least 6 y and supporting heterologous prime-boost strategies for pandemic preparedness against emerging H5 outbreaks."

Clinical • Journal • Preclinical • Infectious Disease • Influenza • Respiratory Diseases

SECONDARY COMPLICATIONS OF INFLUENZA AND ANTIBIOTIC PRESCRIPTIONS THAT COULD BE PREVENTED BY CELL-BASED COMPARED TO EGG-BASED INFLUENZA VACCINES IN THE PAEDIATRIC POPULATION, UNITED STATES, 2023-2024 (ESPID 2026) - "Use of cell-based instead of egg-based vaccine was estimated to additionally prevent 23,364 episodes of acute otitis media, 12,408 asthma exacerbations, 5,932 episodes of acute bronchitis and 1,937 bacterial pneumonia cases, as well as 92,486 antibiotic prescriptions. Conclusions/Learning Points In the paediatric population, use of a more effective cell-based influenza vaccine could confer substantial public health benefits beyond influenza prevention, through clinically meaningful reductions in secondary complications and antibiotic use, supporting improved antibiotic stewardship."

Clinical • Infectious Disease • Influenza

CLINICAL AND ECONOMIC BENEFITS OF CELL-BASED VERSUS EGG- BASED INFLUENZA VACCINES IN U.S. CHILDREN: A DYNAMIC MODELING ANALYSIS (ESPID 2026) - "Conclusions/Learning Points Cell-based influenza vaccines significantly reduce outpatient visits, hospitalizations, and associated costs compared to egg-based vaccines in U.S. children. These findings highlight their potential as a cost- effective strategy to improve health outcomes and alleviate influenza's economic burden."

Clinical • HEOR • Infectious Disease • Influenza

ECONOMIC AND CLINICAL OUTCOMES OF CELL-BASED VERSUS EGG-BASED INFLUENZA VACCINES IN U.S. PEDIATRIC AND ADULT POPULATIONS: A MODELING STUDY (ISPOR 2026) - "Improving pediatric and adult influenza vaccination rates, alongside the adoption of cost-effective strategies such as cell-based vaccines, has the potential to significantly reduce direct medical expenditures, alleviate healthcare system burden, and advance national public health goals."

Clinical • Clinical data • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

PRODUCTIVITY IMPACT OF CELL-BASED VERSUS EGG-BASED INFLUENZA VACCINES IN U.S. PEDIATRIC AND ADULT POPULATIONS: A MODELING STUDY (ISPOR 2026) - "Adopting cell-based influenza vaccines for pediatric and adult populations can significantly decrease lost workdays—both directly and through reduced caregiver absenteeism—alleviating economic and productivity burdens on U.S. payers and employers and supporting national public health objectives."

Clinical • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF THE TRIVALENT ADJUVANTED INFLUENZA VACCINE IN PEOPLE OVER 50 YEARS OF AGE FOR ARGENTINA (ISPOR 2026) - "Implementing aTIV in high-risk adults aged 50-64 years and adults aged ≥ 65 years would be both cost-effective and affordable for the health system in Argentina. These findings support the consolidation and potential expansion of current vaccination strategies to reduce influenza burden."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Influenza • Respiratory Diseases

Economic Impact of Pediatric Influenza Vaccination Coverage in the United States: A Modeling Analysis of Direct Medical Costs (PAS 2026) - "At the current U.S. influenza vaccination rate in pediatric population (~50%), total estimated influenza-associated medical costs during a high-incidence season amounted to US$251M for outpatient care and US$530M for inpatient care. In a low-incidence season, these costs were US$88M (outpatient) and US$170M (inpatient). Achieving the Healthy People 2030 target vaccination rate (70%) would yield significant economic savings: approximately US$125M during high-incidence seasons and US$79M during low-incidence seasons.Conclusion(s): Improving pediatric influenza vaccination rates to recommended targets represents a highly cost-effective strategy, with the potential to significantly reduce direct medical expenditures, alleviate healthcare system burden, and support national public health goals."

Clinical • HEOR • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines Across Paediatric Populations During the 2023–24 Influenza Season in the United States (PAS 2026) - "The dataset included 60,990 vaccinated and influenza-tested pediatric patients, of whom 7,194 (11.8%) received QIVc and 53,796 (88.2%) received QIVe. QIVc was significantly more effective than QIVe in preventing test-confirmed influenza in the full pediatric population, with an estimated rVE of 19.6% (95% CI: 13.6-25.3%). Consistent rVE results were observed across both pediatric age subgroups and in the outpatient setting (Figure 1)."

Clinical • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Modeling the Impact of Pediatric Influenza Vaccination Rates on U.S. Healthcare Resource Utilization (PAS 2026) - No abstract available

Clinical • HEOR • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Immunogenicity and safety of MF59-adjuvanted H5N1 pandemic influenza vaccine in healthy infants and children: a phase 2 randomized, observer-blind, multicenter study. (PubMed, Vaccine) - "Higher MF59 content was associated with a greater magnitude and persistence of immune responses but was not associated with increased reactogenicity. These data confirm that aH5N1 containing 7.5 μg HA plus 0.25 mL MF59 is immunogenic with an acceptable safety and reactogenicity profile in children."

Clinical • Journal • P2 data • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study (ASH 2024) - "This study also emphasizes the clinical impact of BKVD, demonstrating a significant association with increased risk of NRM after allo-HCT. These findings highlight the need to develop anti-BK virus therapeutics, including cellular therapies, to improve patient outcomes."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Transplantation

Evaluating the Cost-Effectiveness of Adjuvanted Influenza Vaccine in the Older Adult Population in the Netherlands (ISPOR-EU 2025) - "With an assumed rVE of 13.7%, replacing SD-IV with aIV in adults aged ≥60 years in the Netherlands would have been a cost-effective strategy, with ICERs consistently below the commonly accepted willingness-to-pay threshold."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Influenza • Respiratory Diseases

ECAS01 Early Career Scientists workshop - Communicating science - invitation only - with the support of CSL Seqirus and Sanofi (ESWI 2025) - No abstract available

Infectious Disease

Pooled Long-Term Safety Analysis of a Phase 1/2/3 Randomized, Observer-Blind, Controlled Study of the Self-Amplifying mRNA COVID-19 Vaccine ARCT-154 in Adults (ESWI 2025) - No abstract available

Clinical • P1/2 data • Infectious Disease • Novel Coronavirus Disease

ECAS02 Early Career Scientists event and panel discussion "Life after Phd" - invitation only - with the support of AstraZeneca, CSL Seqirus and Sanofi (ESWI 2025) - No abstract available

Infectious Disease

SAT07 Satellite Symposium organised by CSL Seqirus: Addressing the evolving influenza landscape: a public health imperative (ESWI 2025) - No abstract available

Infectious Disease • Influenza

Immunogenicity and safety of high dose formulations of mf59-adjuvanted cell-derived influenza vaccine in adults aged 50 years and older: two phase 2 randomised controlled trials (ESWI 2025) - No abstract available

Clinical • P2 data • Infectious Disease • Influenza

Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg Based Influenza Vaccines During the 2023–2024 Season in the United States (ESWI 2025) - No abstract available

Infectious Disease • Influenza

Immunogenicity of Homologous or Heterologous Booster Vaccinations with MF59-Adjuvanted, Cell Culture–Derived H5N8 or H5N6 Influenza Vaccines in Healthy Subjects Aged ≥18 Years (ESWI 2025) - No abstract available

Preclinical • Infectious Disease • Influenza

Comparable Vaccine Effectiveness of Adjuvanted and High-Dose Influenza Vaccines in Preventing Test-Confirmed Influenza Outcomes, including Hospitalization, in Overall and High-Risk Older Adults: A Test-Negative Design Study During 2022-2023 and 2023-2024 (IDWeek 2025) - No abstract available

Clinical • Infectious Disease • Influenza

Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg-Based Influenza Vaccines During the 2023–2024 Season in the United States (IDWeek 2025) - No abstract available

Infectious Disease • Influenza